Skip to main content

Table 3 Frequency of serious adverse events according treatment status from 2015 to 2019

From: Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study

Events

Cohorts

GLP-1RA (N = 20,762) N (%)

SGLT-2i (N = 20,762) N (%)

Hypoglycemia

11 (0.05)

1 (0.00)

Ketoacidosis

14 (0.07)

18 (0.09)

Diabetic coma

5 (0.02)

7 (0.03)

Acute kidney failure

12 (0.06)

2 (0.01)

Syncope

70 (0.34)

72 (0.35)

Fractures

241 (1.16)

243 (1.17)

Amputations

53 (0.26)

67 (0.32)

  1. GLP-1RA glucagon-like peptide-1 receptor agonists, SGLT-2i sodium glucose transporter-2 inhibitors;
  2. MACE-3 all cause death, non-fatal myocardial infarction, non-fatal stroke, MACE-4 all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840